MHY-1485 is an activator of mTOR that displays potential as a fertility treatment. In vivo, MHY-1485 increases ovarian explant weights, follicle development, and production of viable, mature oocytes. This compound also inhibits autophagy by preventing fusion of autophagosomes and lysosomes in vitro.
| Cas No. | 326914-06-1 |
|---|---|
| Purity | ≥98% |
| Formula | C17H21N7O4 |
| Formula Wt. | 387.4 |
| IUPAC Name | 4,6-Di(4-morpholinyl)-N-(4-nitrophenyl)-1,3,5-triazin-2-amine |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | M3196 Info Sheet PDF |
|---|
Li C, Siragy HM. (Pro)renin receptor regulates autophagy and apoptosis in podocytes exposed to high glucose. Am J Physiol Endocrinol Metab. 2015 Jun 16. [Epub ahead of print]. PMID: 26081285.
Cheng Y, Kim J, Li XX, et al. Promotion of ovarian follicle growth following mTOR activation: synergistic effects of AKT stimulators. PLoS One. 2015 Feb 24;10(2):e0117769. PMID: 25710488.
Choi YJ, Park YJ, Park JY, et al. Inhibitory effect of mTOR activator MHY1485 on autophagy: suppression of lysosomal fusion. PLoS One. 2012;7(8):e43418. Erratum in: PLoS One. 2013;8(1). PMID: 22927967.
